Europe Acute Respiratory Distress Syndrome (ARDS) Treatment Market

Description

List of Tables

The Europe acute respiratory distress syndrome (ARDS) treatment market is expected to reach USD 2,764,971.40 thousand by 2030, from USD 1,356,879.02 thousand in 2022, growing at the CAGR of 9.7% in the forecast period of 2023 to 2030.

Market Segmentation

Europe Acute Respiratory Distress Syndrome (Ards) Treatment Market, By Type (Mechanical Ventilation, Corticosteroids, Antiviral Medication, Extracorporeal Membrane Oxygenation (ECMO), Tocilizumab, and Others), Cause ( Sepsis, Inhalation of Harmful Substances, Severe Pneumonia, and Others), Route of Administration (Parenteral, Oral, and Others), End User (Hospitals, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), Country (Germany, France, U.K., Italy, Spain, Turkey, Hungary, Netherlands, Switzerland, Austria Lithuania, Poland, Russia, Ireland, Norway, and rest of Europe) - Industry Trends and Forecast to 2030.

Overview of Europe Acute Respiratory Distress Syndrome (ARDS) Treatment Market Dynamics

Driver
Increasing prevalence and incidence of acute lung injury in the market
Restraint
High cost of device and treatment
Opportunity
Strategic initiatives joined with new product launches by market players

Market Players

Some of the major market players operating in the Europe Acute Respiratory Distress Syndrome (ARDS) market are listed below:

Gilead Sciences, Inc.
Terumo Medical Corporation
Getinge AB.
LivaNova PLC
Medtronic
ResMed
Fisher & Paykel Healthcare Limited.
Dragerwerk AG & Co. KGaA
NIPRO
Fresenius SE & Co. KGaA
Hamilton Medical
Pfizer Inc.
WEINMANN Emergency Medical Technology GmbH + Co. KG
EUROSETS
Armstrong Medical
nice Neotech Medical Systems Pvt. Ltd.
Besmed Health Business Corp.

1 INTRODUCTION 22

1.1 OBJECTIVES OF THE STUDY 22
1.2 MARKET DEFINITION 22
1.3 OVERVIEW OF EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET 22
1.4 LIMITATIONS 24
1.5 MARKETS COVERED 24

2 MARKET SEGMENTATION 26

2.1 MARKETS COVERED 26
2.2 GEOGRAPHICAL SCOPE 27
2.3 YEARS CONSIDERED FOR THE STUDY 28
2.4 CURRENCY AND PRICING 28
2.5 DBMR TRIPOD DATA VALIDATION MODEL 29
2.6 MULTIVARIATE MODELLING 32
2.7 TYPE LIFELINE CURVE 32
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 33
2.9 DBMR MARKET POSITION GRID 34
2.10 MARKET END USER COVERAGE GRID 35
2.11 VENDOR SHARE ANALYSIS 36
2.12 SECONDARY SOURCES 37
2.13 ASSUMPTIONS 37

3 EXECUTIVE SUMMARY 38

4 PREMIUM INSIGHTS 41

4.1 PESTEL ANALYSIS 42
4.2 PORTER'S FIVE FORCES 43
4.3 INSURANCE REIMBURSEMENT 44
- 4.3.1 CENTER FOR MEDICARE SERVICES (CMS)-ELSO (EXTRACORPOREAL LIFE SUPPORT ORGANIZATION) 44
- 4.3.2 HEALTH RESOURCES AND SERVICES ADMINISTRATION 44
- 4.3.3 ABBOTT CODING GUIDE FOR ECMO 45
- 4.3.4 CENTRAL GOVERNMENT HEALTH SCHEME (CGHS) 45
- 4.3.5 CERN HEALTH INSURANCE SCHEME 46
- 4.3.6 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) - (MEDICARE & MEDICAID) 46
- 4.3.7 AMERICAN HOSPITAL ASSOCIATION 47
4.4 PIPELINE ANALYSIS 48
4.5 PRICING ANALYSIS 50

5 MARKET OVERVIEW 51

5.1 DRIVERS 53
- 5.1.1 INCREASING PREVALENCE AND INCIDENCE OF ACUTE LUNG INJURY 53
- 5.1.2 WIDE RANGE OF RISK FACTORS FOR ARDS TREATMENT 53
- 5.1.3 RISING RATE OF AIR POLLUTION AND UNHEALTHY LIFESTYLE 54
- 5.1.4 INCREASING ACCIDENT RATES AND TRAUMA CAUSING ARDS 54
5.2 RESTRAINTS 55
- 5.2.1 COMPLICATIONS ASSOCIATED WITH THE TREATMENT 55
- 5.2.2 HIGH COST OF DEVICES AND TREATMENT 55
5.3 OPPORTUNITIES 56
- 5.3.1 RISING HEALTHCARE EXPENDITURE TO IMPROVE TREATMENT FACILITIES 56
- 5.3.2 STRATEGIC INITIATIVES JOINED WITH NEW PRODUCT LAUNCH BY MARKET PLAYERS 56
- 5.3.3 IMPROVING AWARENESS REGARDING ARD SYNDROME 57
5.4 CHALLENGES 58
- 5.4.1 STRINGENT RULES & REGULATIONS 58
- 5.4.2 MULTIPLE CHALLENGES FACED BY ICU STAFF 59

6 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE 60

6.1 OVERVIEW 61
6.2 MECHANICAL VENTILATION 64
- 6.2.1 HIGH-FLOW NASAL O2 65
- 6.2.2 BI-LEVEL POSITIVE AIRWAY PRESSURE 65
- 6.2.3 CONTINUOUS POSITIVE AIRWAY PRESSURE 65
- 6.2.4 PRONE POSITION VENTILATION 65
- 6.2.5 OTHERS 66
6.3 CORTICOSTEROIDS 66
- 6.3.1 METHYLPREDNISOLONE 67
- 6.3.2 DEXAMETHASONE 67
- 6.3.3 OTHERS 67
6.4 ANTIVIRAL MEDICATION 68
- 6.4.1 RIBAVIRIN 69
- 6.4.2 OSELTAMIVIR 69
- 6.4.3 OTHERS 69
6.5 EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) 69
6.6 TOCILIZUMAB 70
6.7 OTHERS 70

7 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE 71

7.1 OVERVIEW 72
7.2 SEPSIS 75
7.3 INHALATION OF HARMFUL SUBSTANCES 75
7.4 SEVERE PNEUMONIA 76
7.5 OTHERS 76

8 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 77

8.1 OVERVIEW 78
8.2 PARENTERAL 81
- 8.2.1 INTRAVENOUS 81
- 8.2.2 INTRAMUSCULAR 81
8.3 ORAL 82
8.4 OTHERS 82

9 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER 83

9.1 OVERVIEW 84
9.2 HOSPITALS 87
9.3 SPECIALTY CLINICS 87
9.4 HOME HEALTHCARE 88
9.5 OTHERS 88

10 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 89

10.1 OVERVIEW 90
10.2 DIRECT TENDER 93
10.3 HOSPITAL PHARMACY 93
10.4 RETAIL PHARMACY 94
10.5 ONLINE PHARMACY 94

11 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION 95

11.1 EUROPE 97
- 11.1.1 GERMANY 102
- 11.1.2 FRANCE 107
- 11.1.3 U.K. 112
- 11.1.4 ITALY 117
- 11.1.5 SPAIN 122
- 11.1.6 TURKEY 127
- 11.1.7 NETHERLANDS 132
- 11.1.8 SWITZERLAND 137
- 11.1.9 BELGIUM 142
- 11.1.10 RUSSIA 147
- 11.1.11 REST OF EUROPE 152

12 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, COMPANY LANDSCAPE 153

12.1 COMPANY SHARE ANALYSIS: EUROPE 153

13 SWOT ANALYSIS 154

14 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT, CPS 155

14.1 GILEAD SCIENCES INC. 155
- 14.1.1 COMPANY SNAPSHOT 155
- 14.1.2 REVENUE ANALYSIS 156
- 14.1.3 COMPANY SHARE ANALYSIS 156
- 14.1.4 PRODUCT PORTFOLIO 157
- 14.1.5 RECENT DEVELOPMENT 157
14.2 TERUMO CORPORATION 158
- 14.2.1 COMPANY SNAPSHOT 158
- 14.2.2 REVENUE ANALYSIS 158
- 14.2.3 COMPANY SHARE ANALYSIS 159
- 14.2.4 PRODUCT PORTFOLIO 159
- 14.2.5 RECENT DEVELOPMENT 159
14.3 GETINGE 160
- 14.3.1 COMPANY SNAPSHOT 160
- 14.3.2 REVENUE ANALYSIS 160
- 14.3.3 COMPANY SHARE ANALYSIS 161
- 14.3.4 PRODUCT PORTFOLIO 161
- 14.3.5 RECENT DEVELOPMENT 161
14.4 LIVANOVA PLC 162
- 14.4.1 COMPANY SNAPSHOT 162
- 14.4.2 REVENUE ANALYSIS 162
- 14.4.3 COMPANY SHARE ANALYSIS 163
- 14.4.4 PRODUCT PORTFOLIO 163
- 14.4.5 RECENT DEVELOPMENTS 163
14.5 MEDTRONIC 164
- 14.5.1 COMPANY SNAPSHOT 164
- 14.5.2 REVENUE ANALYSIS 164
- 14.5.3 COMPANY SHARE ANALYSIS 165
- 14.5.4 PRODUCT PORTFOLIO 165
- 14.5.5 RECENT DEVELOPMENTS 165
14.6 ARMSTRONG MEDICAL 166
- 14.6.1 COMPANY SNAPSHOT 166
- 14.6.2 PRODUCT PORTFOLIO 166
- 14.6.3 RECENT DEVELOPMENT 166
14.7 BESMED HEALTH BUSINESS CORP. 167
- 14.7.1 COMPANY SNAPSHOT 167
- 14.7.2 PRODUCT PORTFOLIO 167
- 14.7.3 RECENT DEVELOPMENTS 168
14.8 DRAGERWERK AG & CO. KGAA 169
- 14.8.1 COMPANY SNAPSHOT 169
- 14.8.2 REVENUE ANALYSIS 169
- 14.8.3 PRODUCT PORTFOLIO 170
- 14.8.4 RECENT DEVELOPMENTS 170
14.9 EUROSETS 171
- 14.9.1 COMPANY SNAPSHOT 171
- 14.9.2 PRODUCT PORTFOLIO 171
- 14.9.3 RECENT DEVELOPMENT 171
14.10 FISHER & PAYKEL HEALTHCARE LIMITED 172
- 14.10.1 COMPANY SNAPSHOT 172
- 14.10.2 REVENUE ANALYSIS 172
- 14.10.3 PRODUCT PORTFOLIO 173
- 14.10.4 RECENT DEVELOPMENTS 173
14.11 FRESENIUS SE & CO. KGAA. 174
- 14.11.1 COMPANY SNAPSHOT 174
- 14.11.2 REVENUE ANALYSIS 174
- 14.11.3 PRODUCT PORTFOLIO 175
- 14.11.4 RECENT DEVELOPMENT 175

14.12 HAMILTON MEDICAL 176
- 14.12.1 COMPANY SNAPSHOT 176
- 14.12.2 PRODUCT PORTFOLIO 176
- 14.12.3 RECENT DEVELOPMENT 176
14.13 NICE NEOTECH MEDICAL SYSTEMS PVT.LTD. 177
- 14.13.1 COMPANY SNAPSHOT 177
- 14.13.2 PRODUCT PORTFOLIO 177
- 14.13.3 RECENT DEVELOPMENT 177
14.14 NIPRO 178
- 14.14.1 COMPANY SNAPSHOT 178
- 14.14.2 REVENUE ANALYSIS 178
- 14.14.3 PRODUCT PORTFOLIO 179
- 14.14.4 RECENT DEVELOPMENT 179
14.15 PFIZER INC. 180
- 14.15.1 COMPANY SNAPSHOT 180
- 14.15.2 REVENUE ANALYSIS 180
- 14.15.3 PRODUCT PORTFOLIO 181
- 14.15.4 RECENT DEVELOPMENT 181
14.16 RESMED 182
- 14.16.1 COMPANY SNAPSHOT 182
- 14.16.2 REVENUE ANALYSIS 182
- 14.16.3 PRODUCT PORTFOLIO 183
- 14.16.4 RECENT DEVELOPMENT 183
14.17 WEINMANN EMERGENCY MEDICAL TECHNOLOGY GMBH + CO. KG 184
- 14.17.1 COMPANY SNAPSHOT 184
- 14.17.2 PRODUCT PORTFOLIO 184
- 14.17.3 RECENT DEVELOPMENT 184

15 QUESTIONNAIRE 185

16 RELATED REPORTS 188

LIST OF TABLES

TABLE 1 LIST OF PRICES FOR APPROVED DRUGS FOR ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT 50
TABLE 2 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 63
TABLE 3 EUROPE MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 64
TABLE 4 EUROPE MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 64
TABLE 5 EUROPE MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 65
TABLE 6 EUROPE MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 65
TABLE 7 EUROPE CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 66
TABLE 8 EUROPE CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 66
TABLE 9 EUROPE CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 67
TABLE 10 EUROPE CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 67
TABLE 11 EUROPE ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 68
TABLE 12 EUROPE ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 68
TABLE 13 EUROPE ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 68
TABLE 14 EUROPE ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 68
TABLE 15 EUROPE EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 69
TABLE 16 EUROPE TOCILIZUMAB IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 70
TABLE 17 EUROPE OTHERS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 70
TABLE 18 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND) 74
TABLE 19 EUROPE SEPSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 75
TABLE 20 EUROPE INHALATION OF HARMFUL SUBSTANCES IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 75
TABLE 21 EUROPE SEVERE PNEUMONIA IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 76
TABLE 22 EUROPE OTHERS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 76
TABLE 23 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 80
TABLE 24 EUROPE PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 81
TABLE 25 EUROPE PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 81
TABLE 26 EUROPE ORAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 82
TABLE 27 EUROPE OTHERS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 82
TABLE 28 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 86
TABLE 29 EUROPE HOSPITALS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 87
TABLE 30 EUROPE SPECIALTY CLINICS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 87
TABLE 31 EUROPE HOME HEALTHCARE IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 88
TABLE 32 EUROPE OTHERS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 88
TABLE 33 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 92
TABLE 34 EUROPE DIRECT TENDER IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 93
TABLE 35 EUROPE HOSPITAL PHARMACY IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 93
TABLE 36 EUROPE RETAIL PHARMACY IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 94
TABLE 37 EUROPE ONLINE PHARMACY IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 94
TABLE 38 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND) 97
TABLE 39 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 98
TABLE 40 EUROPE MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 98
TABLE 41 EUROPE MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 99
TABLE 42 EUROPE CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 99
TABLE 43 EUROPE CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 99
TABLE 44 EUROPE ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 99
TABLE 45 EUROPE ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 100
TABLE 46 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND) 100
TABLE 47 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 100
TABLE 48 EUROPE PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 101
TABLE 49 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 101
TABLE 50 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 101
TABLE 51 GERMANY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 102
TABLE 52 GERMANY MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 102
TABLE 53 GERMANY MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 103
TABLE 54 GERMANY MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 103
TABLE 55 GERMANY CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 103
TABLE 56 GERMANY CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 104
TABLE 57 GERMANY CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 104
TABLE 58 GERMANY ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 104
TABLE 59 GERMANY ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 104
TABLE 60 GERMANY ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 105
TABLE 61 GERMANY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND) 105
TABLE 62 GERMANY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 105
TABLE 63 GERMANY PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 106
TABLE 64 GERMANY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 106
TABLE 65 GERMANY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 106
TABLE 66 FRANCE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 107
TABLE 67 FRANCE MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 107
TABLE 68 FRANCE MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 108
TABLE 69 FRANCE MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 108
TABLE 70 FRANCE CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 108
TABLE 71 FRANCE CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 109
TABLE 72 FRANCE CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 109
TABLE 73 FRANCE ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 109
TABLE 74 FRANCE ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 109
TABLE 75 FRANCE ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 110
TABLE 76 FRANCE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND) 110
TABLE 77 FRANCE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 110
TABLE 78 FRANCE PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 111
TABLE 79 FRANCE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 111
TABLE 80 FRANCE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 111
TABLE 81 U.K. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 112
TABLE 82 U.K. MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 112
TABLE 83 U.K. MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 113
TABLE 84 U.K. MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 113
TABLE 85 U.K. CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 113
TABLE 86 U.K. CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 114
TABLE 87 U.K. CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 114
TABLE 88 U.K. ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 114
TABLE 89 U.K. ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 114
TABLE 90 U.K. ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 115
TABLE 91 U.K. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND) 115
TABLE 92 U.K. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 115
TABLE 93 U.K. PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 116
TABLE 94 U.K. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 116
TABLE 95 U.K. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 116
TABLE 96 ITALY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 117
TABLE 97 ITALY MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 117
TABLE 98 ITALY MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 118
TABLE 99 ITALY MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 118
TABLE 100 ITALY CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 118
TABLE 101 ITALY CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 119
TABLE 102 ITALY CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 119
TABLE 103 ITALY ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 119
TABLE 104 ITALY ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 119
TABLE 105 ITALY ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 120
TABLE 106 ITALY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND) 120
TABLE 107 ITALY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 120
TABLE 108 ITALY PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 121
TABLE 109 ITALY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 121
TABLE 110 ITALY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 121
TABLE 111 SPAIN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 122
TABLE 112 SPAIN MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 122
TABLE 113 SPAIN MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 123
TABLE 114 SPAIN MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 123
TABLE 115 SPAIN CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 123
TABLE 116 SPAIN CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 124
TABLE 117 SPAIN CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 124
TABLE 118 SPAIN ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 124
TABLE 119 SPAIN ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 124
TABLE 120 SPAIN ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 125
TABLE 121 SPAIN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND) 125
TABLE 122 SPAIN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 125
TABLE 123 SPAIN PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 126
TABLE 124 SPAIN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 126
TABLE 125 SPAIN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 126
TABLE 126 TURKEY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 127
TABLE 127 TURKEY MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 127
TABLE 128 TURKEY MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 128
TABLE 129 TURKEY MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 128
TABLE 130 TURKEY CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 128
TABLE 131 TURKEY CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 129
TABLE 132 TURKEY CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 129
TABLE 133 TURKEY ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 129
TABLE 134 TURKEY ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 129
TABLE 135 TURKEY ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 130
TABLE 136 TURKEY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND) 130
TABLE 137 TURKEY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 130
TABLE 138 TURKEY PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 131
TABLE 139 TURKEY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 131
TABLE 140 TURKEY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 131
TABLE 141 NETHERLANDS ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 132
TABLE 142 NETHERLANDS MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 132
TABLE 143 NETHERLANDS MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 133
TABLE 144 NETHERLANDS MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 133
TABLE 145 NETHERLANDS CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 133
TABLE 146 NETHERLANDS CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 134
TABLE 147 NETHERLANDS CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 134
TABLE 148 NETHERLANDS ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 134
TABLE 149 NETHERLANDS ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 134
TABLE 150 NETHERLANDS ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 135
TABLE 151 NETHERLANDS ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND) 135
TABLE 152 NETHERLANDS ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 135
TABLE 153 NETHERLANDS PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 136
TABLE 154 NETHERLANDS ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 136
TABLE 155 NETHERLANDS ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 136
TABLE 156 SWITZERLAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 137
TABLE 157 SWITZERLAND MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 137
TABLE 158 SWITZERLAND MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 138
TABLE 159 SWITZERLAND MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 138
TABLE 160 SWITZERLAND CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 138
TABLE 161 SWITZERLAND CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 139
TABLE 162 SWITZERLAND CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 139
TABLE 163 SWITZERLAND ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 139
TABLE 164 SWITZERLAND ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 139
TABLE 165 SWITZERLAND ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 140
TABLE 166 SWITZERLAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND) 140
TABLE 167 SWITZERLAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 140
TABLE 168 SWITZERLAND PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 141
TABLE 169 SWITZERLAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 141
TABLE 170 SWITZERLAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 141
TABLE 171 BELGIUM ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 142
TABLE 172 BELGIUM MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 142
TABLE 173 BELGIUM MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 143
TABLE 174 BELGIUM MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 143
TABLE 175 BELGIUM CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 143
TABLE 176 BELGIUM CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 144
TABLE 177 BELGIUM CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 144
TABLE 178 BELGIUM ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 144
TABLE 179 BELGIUM ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 144
TABLE 180 BELGIUM ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 145
TABLE 181 BELGIUM ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND) 145
TABLE 182 BELGIUM ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 145
TABLE 183 BELGIUM PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 146
TABLE 184 BELGIUM ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 146
TABLE 185 BELGIUM ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 146
TABLE 186 RUSSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 147
TABLE 187 RUSSIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 147
TABLE 188 RUSSIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 148
TABLE 189 RUSSIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 148
TABLE 190 RUSSIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 148
TABLE 191 RUSSIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 148
TABLE 192 RUSSIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 149
TABLE 193 RUSSIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 149
TABLE 194 RUSSIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 149
TABLE 195 RUSSIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 149
TABLE 196 RUSSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND) 150
TABLE 197 RUSSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 150
TABLE 198 RUSSIA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 150
TABLE 199 RUSSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 151
TABLE 200 RUSSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 151
TABLE 201 REST OF EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 152

LIST OF FIGURES

FIGURE 1 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: SEGMENTATION 26
FIGURE 2 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: DATA TRIANGULATION 29
FIGURE 3 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: DROC ANALYSIS 30
FIGURE 4 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: EUROPE VS REGIONAL MARKET ANALYSIS 31
FIGURE 5 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: COMPANY RESEARCH ANALYSIS 31
FIGURE 6 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: INTERVIEW DEMOGRAPHICS 33
FIGURE 7 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: DBMR MARKET POSITION GRID 34
FIGURE 8 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: MARKET END USER COVERAGE GRID 35
FIGURE 9 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: VENDOR SHARE ANALYSIS 36
FIGURE 10 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: SEGMENTATION 40
FIGURE 11 INCREASING PREVALENCE AND INCIDENCE OF ACUTE LUNG INJURY ARE EXPECTED TO DRIVE THE EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET IN THE FORECAST PERIOD OF 2022 TO 2030 41
FIGURE 12 MECHANICAL VENTILATION SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET IN 2023 & 2030 41
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET 52
FIGURE 14 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY TYPE, 2022 61
FIGURE 15 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY TYPE, 2023-2030 (USD THOUSAND) 62
FIGURE 16 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY TYPE, CAGR (2023-2030) 62
FIGURE 17 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY TYPE, LIFELINE CURVE 63
FIGURE 18 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY CAUSE, 2022 72
FIGURE 19 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY CAUSE, 2023-2030 (USD THOUSAND) 73
FIGURE 20 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY CAUSE, CAGR (2023-2030) 73
FIGURE 21 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY CAUSE, LIFELINE CURVE 74
FIGURE 22 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2022 78
FIGURE 23 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD THOUSAND) 79
FIGURE 24 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030) 79
FIGURE 25 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE 80
FIGURE 26 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY END USER, 2022 84
FIGURE 27 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY END USER, 2023-2030 (USD THOUSAND) 85
FIGURE 28 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY END USER, CAGR (2023-2030) 85
FIGURE 29 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY END USER, LIFELINE CURVE 86
FIGURE 30 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2022 90
FIGURE 31 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND) 91
FIGURE 32 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 91
FIGURE 33 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 92
FIGURE 34 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: SNAPSHOT (2022) 96
FIGURE 35 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: COMPANY SHARE 2022 (%) 153